前列腺素F1Alpha | 745-62-0

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 前列腺素F1Alpha
• 中文别名: 前列腺素F1α
• 英文名称: (9α,11α,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid
• 英文别名: prostaglandin F_1α；PGF₁α；PGF1a；Prostaglandin f1alpha；7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]heptanoic acid
• CAS: 745-62-0
• 化学式: C₂₀H₃₆O₅
• 分子量: 356.503
• InChiKey: DZUXGQBLFALXCR-CDIPTNKSSA-N

物化性质

• 熔点：
  102.5°C
• 比旋光度：
  +24°(D/24℃)(c=0.87,THF)
• 沸点：
  409.31°C (rough estimate)
• 密度：
  1.0321 (rough estimate)
• 溶解度：
  DMF：50 mg/ml； DMSO：50 mg/ml；乙醇：50 mg/ml； PBS pH 7.2：2 mg/ml
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  25
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  5

安全信息

• 安全说明：
  S22,S24/25
• WGK Germany：
  3

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Prostaglandin F1α
CAS-No. : 745-62-0

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
: (9α,11α,13E,15S)-9,11,15-Trihydroxyprost-13-en-1-oic acid
Synonyms
PGF1α
Formula : C20H36O5
Molecular Weight : 356,50 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: -20 °C
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing 95 - 97 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility 0,002 g/l at 25 °C
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
Genotoxicity in vivo - mouse - Intraperitoneal
sperm
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
Reproductive toxicity - rat - Subcutaneous
Effects on Fertility: Pre-implantation mortality (e.g., reduction in number of implants per female; total
number of implants per corpora lutea). Effects on Fertility: Other measures of fertility
Reproductive toxicity - mouse - Subcutaneous
Paternal Effects: Spermatogenesis (including genetic material, sperm morphology,motility, and count).
Paternal Effects: Prostate, seminal vessicle, Cowper's gland, accessory glands.
Reproductive toxicity - mouse - Subcutaneous
Effects on Fertility: Post-implantation mortality (e.g., dead and/or resorbed implants per total number of
implants). Effects on Embryo or Fetus: Fetal death.
Developmental Toxicity - rat - Subcutaneous
Effects on Embryo or Fetus: Extra embryonic structures (e.g., placenta, umbilical cord). Effects on Embryo
or Fetus: Fetotoxicity (except death, e.g., stunted fetus).
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes
May cause eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: GY4569700

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备方法

生化研究

用途简介

反应信息

• 作为反应物：
  描述：

  前列腺素F1Alpha 生成 7-[(1R,5S)-5-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-3-oxocyclopentyl]heptanoic acid
  参考文献：
  名称：

  NOERI, REDZI;SUDZUKI, MASIAKI

  摘要：

  DOI：
• 作为产物：
  描述：

  7-[(1R,2R,3R,5S)-2-[(E)-3-[tert-butyl(dimethyl)silyl]oxyoct-1-enyl]-3,5-dihydroxycyclopentyl]heptanoic acid 生成 前列腺素F1Alpha
  参考文献：
  名称：

  MARINO, JOSEPH P.;FERNANDEZ, DE LA PRADILLA ROBERTO;LABORDE, EDGARDO, J. ORG. CHEM., 52,(1987) N 22, 4898-4913

  摘要：

  DOI：

文献信息

• The synthesis of PGF1α by re-structuring of castor oil
  作者：D. Ranganathan、S. Ranganathan、M.M. Mehrotra

  DOI：10.1016/0040-4020(80)80089-5

  日期：1980.1

  oil has been transformed—via methyl ricinoleate—to PGF1α by strategy wherein 16 of the 18 carbons of the castor oil backbone are incorporated in the C-20 PGF1α, involving, inter alia, a novel procedure for the regiospecific functionalisation of terminal olefins, a novel degradation of aldehyde to lower acid and strategies useful for the generation of the highly functionalised prostanoid system, which

  蓖麻油已被改造-经由蓖麻油酸甲酯到PGF 1个α由策略，其中所述18个碳原子的蓖麻油骨架的16中的C-20 PGF并入1 α，涉及，除其他外，对于区域专一性官能一种新颖的过程末端烯烃的合成，醛向低级酸的新降解以及可用于生成高度官能化的类前列腺素系统的策略，这些方法特别说明了MEM保护基在多种化学转化中的效用。此外，此工作描述了具有潜在效用和新颖的均PGP的合成合成子的制备1 α。
• METHOD FOR INTRODUCING SUBSTITUENT INTO alpha,beta-UNSATURATED KETONE AND METHOD FOR SYNTHESIZING PROSTAGLANDIN USING THE SAME
  申请人：NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY

  公开号：US20210355061A1

  公开（公告）日：2021-11-18

  The present invention provides a method for introducing substituents into the α-position and the β-position of an α,β-unsaturated ketone, which not only can be used for the synthesis of a prostaglandin by a three-component coupling process, but also enables synthesis of a prostaglandin in a high yield by one-pot operation without requiring the use of a large excess amount of any of the three components required for the synthesis or using a highly toxic heavy metal as a catalyst or a solvent that is highly toxic to living bodies, and a method for synthesizing a prostaglandin using the same technical means. The method for introducing substituents into an α,β-unsaturated ketone according to the present invention is a method for introducing substituents into the carbon at the α-position and the carbon at the β-position of an α,β-unsaturated ketone, including: a first step of mixing alkyllithium and trialkylalkenyl tin in which tin atom binds to the vinyl position of the alkenyl group; a second step of mixing the mixture of the first step and dialkylzinc; a third step of mixing the mixture of the second step and an α,β-unsaturated ketone; and a fourth step of mixing the mixture of the third step and a trifluoromethanesulfonate compound.

  本发明提供了一种将取代基引入α，β-不饱和酮的α位和β位的方法，不仅可用于通过三组分偶联过程合成前列腺素，还能够通过一锅法高产率合成前列腺素，而无需使用大量超量的三种合成所需组分之一，也无需使用高毒性重金属作为催化剂或对生物体高毒的溶剂，并提供了一种利用相同技术手段合成前列腺素的方法。 根据本发明，将取代基引入α，β-不饱和酮的方法是一种将取代基引入α，β-不饱和酮的α位和β位碳的方法，包括：第一步，混合烷基锂和三烷基烯基锡，其中锡原子与烯基团的乙烯位结合；第二步，混合第一步的混合物和二烷基锌；第三步，混合第二步的混合物和α，β-不饱和酮；第四步，混合第三步的混合物和三氟甲磺酸盐化合物。
• Prostaglandin phosphonic acids through homolytic halodecarboxylation of prostaglandins F1α and F2α
  作者：Andrew S. Kendea、Jared B.J. Milbanka、Frank H. Ebetino、Mitchell A. deLong

  DOI：10.1016/s0040-4039(99)01675-5

  日期：1999.11

  derivatives of prostaglandins F1α and F2α were prepared through Arbuzov reaction of 2-decarboxy-2-iodoprostaglandin intermediates. The intermediate iodo compounds, which are potentially valuable for the synthesis of other analogs, were obtained from the parent prostaglandins by Barton's modification of the Hunsdiecker reaction.

  前列腺素的F膦酸衍生物1α和F 2α通过阿尔布佐夫反应，制备2-脱羧-2- iodoprostaglandin中间体。通过Barton对Hunsdiecker反应的修饰，从母体前列腺素获得了可能对合成其他类似物有价值的中间体碘化合物。
• Improved Process for the Production of Prostaglandins and Prostaglandin Analogs
  申请人：SANDOZ AG

  公开号：EP2143712A1

  公开（公告）日：2010-01-13

  The present invention relates to an improved process for the production of prostaglandins and prostaglandin analogs. In particular, this invention relates to the production of prostaglandins of the PGF2α-series, including latanoprost, travoprost, and bimatoprost, which are active pharmaceutical ingredients used for the reduction of elevated intraocular pressure in patients with glaucoma and ocular hypertension.

  本发明涉及一种改进的用于生产前列腺素和前列腺素类似物的过程。具体而言，本发明涉及PGF2α系列前列腺素的生产，包括拉坦前列醇、曲普前列醇和比马前列醇，这些是用于降低青光眼和眼内高压患者眼内压的活性药用成分。
• AMINO ACID SALTS OF PROSTAGLANDINS
  申请人：DeLong Mitchell A.

  公开号：US20100105775A1

  公开（公告）日：2010-04-29

  The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.

  本发明涉及新型氨基酸前列腺素盐及其制备和使用方法。